1. Successful postcoital testing of Ovaprene: An investigational non-hormonal monthly vaginal contraceptive
- Author
-
Mauck, Christine, Thurman, Andrea, Jensen, Jeffrey T, Schreiber, Courtney A, Baker, Jeff, Hou, Melody Y, Chavoustie, Steven, Dart, Clint, Wu, Hongsheng, Zack, Nadene, Hatheway, Jessica, and Friend, David
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Contraception/Reproduction ,Clinical Research ,Clinical Trials and Supportive Activities ,Prevention ,Reproductive health and childbirth ,Good Health and Well Being ,Male ,Pregnancy ,Humans ,Female ,Semen ,Contraceptive Devices ,Female ,Vagina ,Body Mass Index ,Contraceptive Agents ,Contraception ,Contraceptive ,Ovaprene ,Postcoital test ,Vaginal ,Clinical Sciences ,Paediatrics and Reproductive Medicine ,Public Health and Health Services ,Obstetrics & Reproductive Medicine ,Clinical sciences ,Reproductive medicine ,Health services and systems - Abstract
ObjectiveEvaluate reduction in progressively motile sperm per high power field (HPF) in midcycle cervical mucus after intercourse with Ovaprene: an investigational monthly non-hormonal vaginal contraceptive consisting of a vaginal ring and mechanical barrier, releasing spermiostatic ferrous gluconate.Study designOpen-label, multicenter study enrolling heterosexually-active women with previous permanent contraception. Participants underwent a baseline postcoital test cycle with no device to confirm the presence of sperm, followed by one diaphragm postcoital test cycle, one Ovaprene safety cycle, and two Ovaprene postcoital test cycles. In each postcoital test cycle, participants underwent a midcycle cervical mucus evaluation to confirm an Insler score ≥10 and absence of sperm, and then returned two to four hours after vaginal intercourse for repeat cervical mucus evaluation. We considered
- Published
- 2024